FibroBiologics, Inc. Common Stock
FBLG
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.6M
$1.21
▼ -7.31%
P/E
—
Mkt Cap
$2.6M
52-Wk Range
$0.62–$11.40
52-Week Range
$0.62 - $11.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 88.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary fibroblast-based cell therapy platform with broad therapeutic applications
- Diversified pipeline spanning multiple high-value disease categories
- Clinical-stage candidates with significant unmet medical needs in target markets
- Experienced leadership team focused on regenerative medicine and cell therapy innovation
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Advancement of CybroCell and CYMS101 through clinical development stages
Value
Valuation data unavailable
Momentum
Hot
+42.7% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying FBLG right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 30, 2026
JUL 31, 2026
Reported EPS of -$0.66 vs -$0.93 consensus (+29.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+29.0%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: Maxim Group · May 4, 2026
vs Industry
How FBLG stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related